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Abstract
Background: Doxorubicin (DOX) is one of the most potent antitumor agents available; however, its clinical use is limited
because of the risk of severe cardiotoxicity. Though numerous studies have ascribed DOX cardiomyopathy to specific
cellular pathways, the precise mechanism remains obscure. Sini decoction (SND) is a well-known formula of Traditional
Chinese Medicine (TCM) and is considered as efficient agents against DOX-induced cardiomyopathy. However, its action
mechanisms are not well known due to its complex components.
Methodology/Principal Findings: A tissue-targeted metabonomic method using gas chromatography–mass spectrometry
was developed to characterize the metabolic profile of DOX-induced cardiomyopathy in mice. With Elastic Net for
classification and selection of biomarkers, twenty-four metabolites corresponding to DOX-induced cardiomyopathy were
screened out, primarily involving glycolysis, lipid metabolism, citrate cycle, and some amino acids metabolism. With these
altered metabolic pathways as possible drug targets, we systematically analyzed the protective effect of TCM SND, which
showed that SND administration could provide satisfactory effect on DOX-induced cardiomyopathy through partially
regulating the perturbed metabolic pathways.
Conclusions/Significance: The results of the present study not only gave rise to a systematic view of the development of
DOX-induced cardiomyopathy but also provided the theoretical basis to prevent or modify expected damage.
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Introduction
Doxorubicin (DOX) is a powerful anticancer antibiotic [1]. The
clinical use of DOX is often limited because of its undesirable
serious cardiotoxic side effects, which frequently lead to congestive
heart failure [2,3,4]. Though numerous studies have ascribed
doxorubicin cardiotoxicity to specific cellular pathways, including
an increase in free radicals formation [5], lipid peroxidation [6],
cardiomyocyte apoptosis [7,8], interference of calcium dynamics
[9], abnormalities in the mitochondria [10,11,12], alteration of
cardiac energetics [13,14,15], irreversible damage of DNA [16]
and other putative mechanisms, the precise mechanism of this
pathogenesis remains obscure. Therefore the biological processes
of doxorubicin-induced cardiomyopathy still need further inves-
tigation to find its biomarkers and illuminate its mechanism.
Medicinal plants play a key role in human health care
nowadays. It is increasingly being understood that the Traditional
Chinese Medicine (TCM) does have a remedy for acute or chronic
disorders. Sini decoction (SND), which is officially recorded in the
Chinese Pharmacopoeia 2010 edition and has been used to
prevent or treat cardiovascular disease as well as DOX-induced
cardiomyopathy for many years [17,18,19,20], is a representative
TCM. It is composed of three medicinal plants: Acontium
carmichaeli, Glycyrrhiza uralensis and Zingiber officinale. As there are
complex components in SND, which can hit multiple targets and
exert an overall therapeutic effect, it is hard to understand its
action mechanisms completely.
Metabonomics, the systems biology approach of small mole-
cules, is a rapidly advancing field that aims to monitor as many
metabolites with low molecular weight as possible rather than
focus on individual metabolite in a single cell, biofluids, and tissue
extracts [21,22]. It provides insights into the global metabolic state
of entire organism, which is well coincident with the integrity and
systemic feature of TCM [23,24]. The emerging metabonomics
has been conducted to analyze doxorubicin related toxicity
biomarkers [25,26]. For example, J. C. Park [25] identified 19
urinary metabolites in rats treated with doxorubicin. Those
identified biomarkers suggested renal dysfunction and liver injury
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Wang [26] showed that tryptophan and phenylalanine metabolism
was also important process in the systemic toxicity of doxorubicin.
Though a lot of urinary biomarkers have been successfully
identified from the systemic toxicity of doxorubicin, the tissue-
specific biomarkers in myocardium still need further study to
provide a new insight into the pathological processes of
doxorubicin-induced cardiomyopathy. Therefore, a gas chroma-
tography–mass spectrometry (GC-MS) method based on a
metabonomic strategy was developed. In addition, the reverse
effects of TCM SND and its mechanisms were also investigated by
using a metabonomic approach for the first time.
Results
Serum biochemical assay
Serum levels of creatine kinases (CK), creatine kinase-MB (CK-
MB) and lactate dehydrogenase (LDH) were significantly elevated
72 h after DOX injection compared with the levels in the control
rats (Figure 1A–C). SND significantly attenuated DOX-induced
increase in the above enzymes in serum, indicative of reduced
myocardial necrosis (p,0.05).
Selection of DOX-induced metabolites
The typical total ion current chromatograms (TICs) of
myocardial extracts are shown in Figure 2. After aligning mass
ions using XCMS software, 1371 ions peaks were obtained,
where a few of these fragment ion peaks were found from the
same silylation derivatives of endogenous metabolites. By
untargeted filtration of ion peaks (It was described in the
Material and Methods section), the data was simplified and
170 ion peaks were obtained. The unsupervised Principal
Component Analysis (PCA) was first applied to explore
correlations between control and DOX groups, and a tendency
in the score plot to separate the two classes was detected
(R
2=0.50) (Figure 3). To further search ion peaks that can
discriminate between groups, a unique challenge is posed because
of a large number of variables, and a few observations. The
traditional partial least squares (PLS) method has extensively
applied to selection of biomarkers in the similar metabonomic
data [27]. Unfortunately, it cannot automatically retain good
features. In this study, a recent developed approach, Elastic Net,
was used for classification and selection of biomarkers [28]. An
advantage of the Elastic Net approach is that some of the effects
of the variables in these models are estimated to be exactly zero.
These will represent variables that have no discriminatory power
between the two classes, while those with nonzero coefficients will
represent variables that can separate classes of groups successful-
ly. Thus, a variable list that can successfully discriminate the
classes could be automatically obtained. Figure 4 shows the
relationship between lambda and deviance using the Elastic Net
approach for the 170 ion peaks with 5-fold cross-validation. We
can found that there was a small deviance for classification when
we selected specific lambda value, an important parameter in
Elastic Net approach, which can produce a classifier with 37
variables plus an intercept term. Thus, 37 variables with nonzero
coefficients were first selected as the candidates of potential
biomarkers. Some of these variables were found to be from the
same metabolites. After merging the variables from the identical
metabolites, 24 metabolites were collected and considered as the
potential biomarkers. To accurately evaluate their changes, the
ratios of their actual peak areas to that of the internal standard in
both control group and DOX group were calculated and then
validated using one-way analysis of variance (ANOVA) (p,0.05).
Finally, it was found that sixteen of 24 metabolites, including L-
alanine, phosphate, glycine, succinate, malate, proline, threonic
acid, glutamine, phenylalanine, dihydroxyacetonephosphate
(DHAP), glycerol-3-phosphate (G-3-P), fructose, glucose, stearic
acid, myo-inositol and cholesterol, were evaluated in the DOX
group, while the other eight metabolites including lactate, b-
hydroxybutyric acid, L-valine, isoleucine, threonine, citrate,
linoleic acid, arachidonic acid, were reduced in the DOX group.
(Table S1).
Effect of SND administration
The effective results of SND for protection of DOX-induced
cardiomyopathy have been shown in Section ‘‘Serum biochem-
ical assay’’. As the 24 potential biomarkers have been found, it is
reasonable to take them as the monitoring indexes for further
investigating the protective mechanisms of SND to DOX-induced
cardiomyopathy. Therefore, the levels of these 24 biomarkers were
introduced as variables to PCA, performed on three groups. As
shown in Figure 5, the DOX plus SND group was closer to the
control group, which might suggest SND can reverse the
pathological process of DOX-induced cardiomyopathy. To further
evaluate the reversed condition of the potential biomarkers by pre-
administration with SND, one-way ANOVA with Tukey post hoc
test was performed by SPSS software. The ratios of relative peak
area of the 24 metabolites to that of ribitol are shown in Figure 6.
Compared to the DOX group, the levels of ten metabolites
including lactate, L-alanine, L-valine, isoleucine, glycine, succi-
nate, malate, phenylalanine, citrate, and stearic acid were
significantly reversed in DOX plus SND group. The other fourteen
metabolites were also reversed at different degrees.
Figure 1. CK, CK-MB, and LDH were significantly elevated in DOX treated rats compared to the control group and to the SND
treated groups. (A) Serum creatine phosphokinase (CK). (B) Serum creatine phosphokinase-MB (CK-MB) and (C) lactate dehydrogenase (LDH). Data
are expressed as mean 6 S.D. *p,0.05 versus DOX group.
doi:10.1371/journal.pone.0027683.g001
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The present study demonstrates, for the first time, a GC-MS-
based metabonomic analysis of DOX-induced cardiomyopathy in
mice, identifying 24 potential biomarkers relevant to the
disturbance of myocardial energy metabolism primarily involving
glycolysis, lipid metabolism, citrate cycle, and some amino acids
metabolism. Furthermore, it was confirmed that Chinese Medi-
cine SND could play its role in DOX-induced cardiomyopathy by
intervening in some metabolic pathways, such as glycolysis, lipid
metabolism, citrate cycle, and some amino acids metabolism,
which might be mapped by restoring alterations in some
biomarkers found in this research.
Among these metabolites, lactate, fructose, glucose, DHAP and
G-3-P are correlated with glycolysis, indicating the modulation of
the glycolytic pathway. A reduced in lactate level was observed in
DOX-induced group. It is conceivable that the reduction should
be accompanied with the regulation of enzymes in the heart. The
lactate dehydrogenase B (LDHB), a subtype of lactate dehydro-
genase mainly existing in myocardium, was recently found to be
up-regulated in the DOX treated cardiomyocytes [29], which
could result in lactate reduction through the conversion of lactate
to pyruvate. The elevated glucose and fructose in DOX-induced
group could result from the decreased utilization of glucose and
other simple sugars, which was compatible with the previous
findings [15,30,31]. The build-up of DHAP together with G-3-P
was also observed in DOX-induced group, which was agreed with
the results of Ronen et al. [32]. A more likely explanation for the
elevation is inhibition of the flux through the glycolytic pathway at
the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
GAPDH catalyses the nicotinamide adenine dinucleotidedepen-
dent conversion of glyceraldehyde-3-phosphate (GADP) into 1,3-
Figure 2. The typical total ions current chromatograms (TICs) of myocardial extract. (A) control group; (B) DOX group; (C) DOX+SND
group.
doi:10.1371/journal.pone.0027683.g002
Figure 3. PCA score plot derived from myocardial extracts GC-
MS spectra concerning control (square) and DOX (circle)
groups.
doi:10.1371/journal.pone.0027683.g003
Figure 4. The relationship between lambda and deviance using
the Elastic Net approach.
doi:10.1371/journal.pone.0027683.g004
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enzyme and a central player in glycolytic pathway. The previous
study confirmed the supposition, where the lower expression of
GAPDH was observed in DOX-induced bovine pulmonary artery
endothelial cells [33].
The citrate cycle is central to aerobic metabolism, facilitating
adequate throughout of substrates derived from carbohydrates,
fatty acids or certain amino acids [34]. Three pivotal intermediates
of citrate cycle were changed in this study, where the low level of
citrate and high level of succinate and malate were observed in
DOX-induced group. It has been reported that DOX-induced
cardiomyopathy is associated with a decreased utilization of both
substrates, fatty acids and glucose [15,35], which could, at least in
part, lead to the reduction of citrate synthesis. However, the
elevation of succinate and malate could result from the regulation
of some key enzymes associated with the citrate cycle. As we know,
the metabolism of succinate and malate depend on succinate
dehydrogenase (SDH) and malate dehydrogenase (MDH). We
speculated that the decrease in activities of SDH and MDH should
be a reason for the accumulation of succinate and malate,
respectively. The previous study by Gnanapragasam et al.
supported that the activities of SDH and MDH indeed decreased
in DOX-treated rats [36].
Lipid metabolism has a key role in DOX-induced cardiomy-
opathy, which has been demonstrated by numerous studies
[37,38,39]. Lipid-based metabolites play an important role in
many biochemistry reactions and are related to many biological
functions. In this study, the levels of one saturated fatty acid
(stearic acid) and two unsaturated fatty acids (arachidonic acid and
linoleic acid) were significantly changed. An interesting finding is
that their changes were quite different, where the saturated fatty
acid was upgraded while the unsaturated fatty acids were
downgraded. The elevated stearic acid in DOX treated mice
could indicate that the b-oxidation of the saturated fatty acid was
inhibited. It is known that b-oxidation of fatty acids is tightly
associated with glycometabolism in the heart. The inhibition of
citrate cycle and oxidative phosphorylation due to DOX
accumulation in the heart should be the main cause of fatty acids
oxidation attenuating. Therefore, the accumulation of acyl-CoA
and NADH should have occurred in DOX-induced cardiocytes.
The down-regulating of two enzymes, carnitine palmitoyltransfer-
ase I (CPTI) and NADH dehydrogenase (NADHD) in DOX-
induced cardiocytes were found by the previous studies [39,40],
which provides the indirect evidence to the speculation. However,
arachidonic acid and linoleic acid, two unsaturated fatty acids,
were present in decreased level in DOX-induced group. One
possible explanation was that DOX caused the peroxidation of
unsaturated fatty acids [6]. The abnormal oxidation status
contributed to excessive oxidation damage on myocardial
mitochondrial. Several studies have reported that the level of
malondialdehyde (MDA), the end product of these unsaturated
fatty acids peroxidation, was increased in DOX-treated mice,
which also indirectly confirmed the supposition [36,41]. In
addition, cholesterol was elevated in DOX-induced group.
Previous studies have been proved that DOX could reduce the
rate of lipolysis [37], suggesting that the accumulation of
cholesterol was a characteristic of DOX-induced cardiotoxicity.
The low levels of valine and isoleucine, two branched-chain
amino acids (BCAAs), were observed in DOX group. BCAAs may
be an important alternative energy substrate for the heart in
myocardial ischemia [42]. It seems that the reduction of ATP
production, due to the inhibition of b-oxidation of fatty acids and
citrate cycle induced by DOX, could lead to the utilization of
BCAAs as energy compensation. GC-MS spectra also showed the
changes of other a-amino acids metabolism, where a decrease in
threonine and a build-up in L-alanine, gylcine, phenylalanine, L-
proline and glutamine were observed in DOX group. a-amino
acids are important energy metabolism precursors and can be
transformed into some biomolecules, such as pyruvate, 2-
oxoglutarate and fumarate, to enter into citrate cycle. One
possible speculation was that oxidative stress caused by DOX lead
to the metabolic remodeling of a-amino acids to meet energy
requirement in myocardium [43]. In addition, the alterations in
myocardial energy metabolism induced by DOX were associated
with ATP depletion and the accumulation of phosphate [44].
Finally, the level of b-hydroxybutyric acid, threonine and myo-
inositol was also changed in myocardial tissue, which was
perplexing corresponding to DOX induction due to lack of
information about their biology pathways.
It was reported that SND could up-regulate B-cell lymphoma-
extra large (Bcl-xl) protein and down-regulate BH3 interacting
domain death agonist protein in DOX-induced cardiomyocytes
[17], resulting in promoting mitochondrial function and reducing
apoptosis, which might be responsible for the protective effect of
SND. In this study, the down-regulation of succinate, malate, and
stearic acid and up-regulation of lactate and citrate were observed
in DOX plus SND group compared with DOX group, which
implied that SND might functionally intervene in glycolysis, lipid
metabolism and citrate cycle. In fact, SND administration
permitted the mean levels of each potential biomarker to reverse
at different degrees. These results combined with the serum
biomedical assay suggested that SND has unique characteristics for
the protective effect on DOX-induced cardiomyopathy. The
potential biomarkers revealed metabolic pathways (glycolysis, lipid
metabolism, citrate cycle, and amino acids metabolism) might be
involved in the protective mechanism of SND. Based on these
discussions, the schematic overview of the potential biomarkers
changing for DOX-induced cardiomyopathy in cardiac muscle
and SND modulation is shown in Figure 7, which is helpful to
understand the development of DOX cardiomyopathy and mode-
of-action of SND.
In conclusion, a metabonomic study of the biochemical profiles
of DOX-induced cardiomyopathy was performed using GC-MS
and multivariate analysis. Such a study allowed the holistic
Figure 5. PCA scores plot derived from myocardial levels of
twenty-four metabolites in control (square), DOX (circle) and
DOX plus SND (diamond) groups.
doi:10.1371/journal.pone.0027683.g005
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for classification and selection of biomarkers, twenty-four metab-
olites primarily involved in glycolysis, citrate cycle, lipid metab-
olism and amino acids metabolism, were screened out and
considered as potential biomarkers corresponding to DOX-
induced cardiomyopathy. Combined with the previous studies,
the metabolites’ change shed new light on DOX cardiomyopathy,
which would be used to understand the development of the disease
and assess drug efficacy as well as and mode-of-action. The GC-
MS-based metabonomic method has been successfully applied to
evaluate the protective effect of TCM SND. Taking the potential
biomarkers found in the study as screening indexes, it revealed that
SND could restore the unbalanced glycolysis, lipid metabolism,
citrate cycle, and amino acids metabolism. Therefore, it is
suggested that TCM SND was a promising potential cardioprotec-
tion agent against DOX-induced toxicity.
Materials and Methods
Ethics Statement
All animal experiments were approved by the Administrative
Committee of Experimental Animal Care and Use of Second
Military Medical University (SCXK(Hu)2007-0005), and con-
formed to the National Institute of Health guidelines on the ethical
use of animals.
Reagents and materials
The assay kits for creatine kinases (CK), creatine kinase-MB
(CK-MB) and lactate dehydrogenase (LDH) were purchased from
Shanghai Fosun Long March Medical Science Co. Methoxyla-
mine hydrochloride, N-methyl-N-(trimethylsilyl)- trifluoracetamide
(MSTFA), pyridine, trimethyl-chlorosilane (TMCS), n-heptane,
acetone, b-hydroxybutyric acid and citrate were purchased from
Sigma-Aldrich (St Louis, MO, USA). Methanol and acetonitrile
are chromatography pure (Merk, Germany). The following
compounds were obtained from Shanghai Jingchun Reagent
Co.: ribitol, lactate, L-alanine, L-valine, phosphate, isoleucine,
glycine, Sodium succinate, threonine, malate, L-proline, L-
threonic acid hemicalcium salt, L-glutamine, phenylalanine,
fructose, glucose, myo-inositol, linoleic acid, stearic acid, arachi-
donic acid and cholesterol.
Acontium carmichaeli (collection in Sichuan, China), Glycyrrhiza
uralensis (collection in Xinjiang, China) and Zingiber officinale
Figure 6. Bar graphs show the relative peak area ratios of the 24 metabolites to ribitol in CTR, DOX, and DOX plus SND groups. Data
are expressed as mean 6 S.D.. *p,0.05 versus DOX group.
doi:10.1371/journal.pone.0027683.g006
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Dekang Medicine Corp. (Shanghai, China) were authenticated by
Lianna Sun (Department of Pharmacognosy, School of Pharmacy,
Second Military Medical University, Shanghai, China).
Preparation of SND and phytochemical investigation
According to the original composition of SND recorded in
Chinese Pharmacopoeia 2010 edition, it was prepared using the
following procedure. The crude drugs of A. carmichaeli 60 g, G.
uralensis 60 g and Z. officinale 40 g were immersed in 1.6 liter water
for 1 h and then decocted to boil for 2 h. The decoction was
filtered through four layers of gauze. Next, the dregs were boiled
once again for 1 h with 1.2 liters of water and the decoction was
filtrated out with the above method. Afterward, the successive
decoctions were merged and condensed by a rotatory evaporator
under reduced pressure. Finally, the extraction solution was made
to a concentration of 1.0 g/mL (expressed as the weight of raw
materials). According to our previous published paper [45], 53
components of SND were identified.
Animal experiments
All animal experiments were performed at the Centre of
Laboratory Animals of the Second Military Medical University
(Shanghai, China) in accordance with the relevant national
legislation and local guidelines. ICR mice, 25,30 g weight, were
purchased from the Shanghai Laboratory Animal Co. Mice were
housed with temperature range from 20uCt o2 5 uC and humidity
range from 50% to 60%. The mice were fed with commercial
aseptic food and tap water ad libitum throughout the experimental
period. The animals were randomly divided into three groups
(n=8). Control group: 200 mL of normal saline were injected i.p.
DOX group: animals of the DOX group received a single dose of
DOX (20 mg/kg, i.p.). DOX plus SND group: the mice were
treated with SND 10 g/kg/BW o.p. for 7 consecutive days as
follows: 4 days before, on the same day, and 2 days after
administration of a single dose of DOX (20 mg/kg, i.p.). The
administration dose in the current study is in accordance with
clinical use. Seventy-two hours after DOX administration, blood
samples were collected for biomedical measurement including
CK, CK-MB and LDH and hearts were rapidly excised and
frozen in liquid nitrogen for metabonomic analysis.
Sample preparation
Myocardial tissue (,50 mg) was homogenized in 200 mL saline
and then centrifuged at 13,0006g for 15 min at 4uC. 100-mL
aliquot of the supernatant was transferred into a centrifuge tube
and spiked with the internal standard (5 mL of 1 mg/ml of ribitol),
followed by adding 400 mL ice cold methanol : acetonitrile :
acetone (1:1:1) into the tube. After vigorous shaking for 30 s and
incubation on ice for 10 min, the mixture was centrifuged at
14,0006g for 15 min to precipitate the protein. The supernatant
(300 mL) was transferred into a GC vial and evaporated to dryness
under N2 stream at room temperature. The derivatization was
performed using methoxyamine pyridine (75 mL; 15 mg/mL) at
70uC for 1 h, followed by MSTFA (75 mL) with 1% TMCS as
catalyst at room temperature for 1 h. n-Heptane (200 mL) was
added to dilute the solution after the derivatization and the
supernatant was used for GC-MS analysis.
GC-MS analysis
The derivatized samples for GC-MS were analyzed on a
Thermo-Finnigan Trace DSQ fasting scanning single-quadrupole
MS (Thermo Electron Corporation) operated at unit mass
resolving power. A 1.0 mL of sample solution was injected with
splitless mode to TB-5MS column (30 m6250 mm60.25 mm) with
helium as the carrier gas at a flow of 1.0 mL/min. The injector
temperature was set at 260uC. The temperature of the ion source
was adjusted to 200uC and that of quadrupole was set at 150uC.
GC-MS was operated using electron impact ionization with a 60–
600 atomic mass unit (amu) scan range. The initial temperature of
column was kept at 70uC for 4 min. Then the temperature was
ramped at 4uC /min to 220uC. Subsequently, the temperature was
increased to 310uCb y8 uC /min and was held for 10 min.
Identification of the interested peaks was performed by searching
the NIST database installed in the Thermo-Finnigan Trace DSQ
GC-MS system and comparing with the peaks of commercial
standards.
Validation of GC-MS method
In order to validate the stability of the GC-MS system, an equal
volume of each sample was pooled together to generate a pooled
quality control (QC) sample [46,47]. This QC sample was
processed as real samples and then was randomly inserted
amongst the real sample queue to be analyzed nine times
accordingly. The system stability was expressed as the relative
standard deviation (RSD) of the relative peak areas, i.e., the ratios
of the peak areas of the metabolites to that of the internal standard.
Eight common extracted ion chromatograms (EICs) shared by
these injections were selected based on their relatively high
abundance levels and wide retention time distribution range in the
chromatogram. The result was 6.47%–12.63%, demonstrating the
robustness of the method. This finding means that differences
amid the test samples from different individuals were more likely
to reflect varied metabolite profiles rather than analytical
variation.
Data processing
Data in instrument-specific format were converted to CDF
format files. The program XCMS was used for nonlinear
alignment of the data in the time domain and automatic
integration and extraction of the peak intensities [48]. XCMS
parameters were default settings except for the following:
fwhm=4, bw=2 and snthersh=3. The output data were
imported into MATLAB software, where data were normalized
using the summation of response of all metabolites in one sample
and then calculated the ratios of the intensities of mass ions to that
of the internal standard fragment ion (m/z 216.9, it is the most
abundance fragment ion for the silylation derivative of ribitol).
It should be noted that GC-MS data inherently contain
apparent variability and complexity such as multiple fragment
ions from a single compound. Directly concatenating the matrices
of processed-MS data is suboptimal as this may result in a matrix
with an unfavorable samples-to-variables ratio [49]. It is necessary
Figure 7. Schematic overview of the metabolites changing for doxorubicin cardiomyopathy in myocardium and SND modulation.
Column value in histograms is expressed as mean 6 S.D.. Metabolites or proteins in red and green represent elevation and inhibition, respectively.
The expression of the proteins was based on the previous studies. Metabolites in black means they were not detected in our experiment. The blue
words are pathway’s names.
doi:10.1371/journal.pone.0027683.g007
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analysis. A simple strategy was untargeted filtration of ion peaks
using our in-house scripts in the MATLAB 7.0 (The MathWorks,
Inc., USA), where the most abundant fragment ion with the same
retention time (the time bin is 0.01 min) was remained and the
other ions were excluded. By untargeted filtration of ion peaks, the
data set was simplified and 170 ion peaks were obtained. The
processed data list was further subjected to statistical analysis.
Statistical analysis
Statistically significant differences in mean values were tested by
one-way ANOVA and the Tukey post hoc test for comparisons of
multiple groups. The differences were considered significant when
p,0.05.
Prior to multivariate analysis, the data list was log-transformed
and normalized. The principal component analysis (PCA) using
SIMCA-P (version 11, Umetrics) was used to uncover unknown
trends in the control, DOX and DOX plus SND groups based on
myocardial metabolites. The Elastic Net using the library
‘‘glmnet’’ in the R environment (http:// www.r-project.org) was
used for classification and selection of significant ion peaks
between control and DOX groups. The significant peak changes
between samples were confirmed by manual quantification by
calculating the area under the peak from raw chromatograms.
Supporting Information
Table S1 The relative levels and one-way ANOVA
results of the potential biomarkers in the myocardial
tissues of control, DOX and DOX plus SND group.
(DOC)
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